Competing with Generics – Executive Summary
14 June, 2018
The Indian Pharmaceuticals Market is witnessing a drive towards generic medicines. Pharmaceutical companies in India may, therefore, need to re-orient their strategies. This Executive Summary sets out Four Strategies that need to be deployed by pharmaceutical companies to more effectively compete in the age of generics.
Accountability: Angst, Awareness, Action
15 March, 2012
India is poised at a crucial juncture in its post-independence history. Accountability, the heartbeat of governance, is under siege. The epidemic of unaccountability lurks beneath India’s myriad tragedies, conquering the spirit of the citizen and con-straining India from unlocking its full economic and social potential.
For more information on this book…Read more
Saving Lives – The Promise of Point of Care Testing
7 July, 2011
The past few years have heralded much excitement around the uses of Point of Care Testing (PoCT). With advancements in electronics, the miniaturisation and digitisation of technology has spilled over into the realm of medical diagnostics. Through portable, transportable and handheld instruments, PoCT is the ability to bring the diagnostic capabilities of a laboratory to the patients’ bedsides. It is effectively a potential solution to some of the health problems that India faces, especially in the context of the heavy burden of infectious diseases that plagues it and its large rural population with limited or no access to testing facilities.
Business Landscape of India
2 January, 2008
India’s growth has been accelerated over the last 20 years. Major multi-national companies have entered India and capitalised on India’s human capital. This article elaborates the economic outlook, foreign trade and the market opportunities to enter the country. It also specifies India’s edge over China.
For more information on our India Entry Strategy…Read more
India’s Evolving Dairy Landscape
28 May, 2018
India’s dairy landscape is rapidly evolving. Dairy players are caught in the throes of a transition, from being local and traditional, to becoming more national and modern FMCG companies. Transformative competitive strategies are now more critical than ever before.
For more information on our Agribusiness & Food consulting practice…Read more
Reluctantly Redundant – The Real Cost of Power
11 December, 2010
India is burdened with a substantial power deficit resulting in vast tracts of the country, living in the dark shadows of frequent power outages. Meanwhile, India’s hapless citizens have already invested around Rs 100,000 crores in power back-up equipment due to the poor reliability of grid power. Unless the government and regulators craft solutions that address the specific power needs of different segments of society, we will all have no option but to invest in and maintain a high-level of power redundancy.
For more information on our Industrials consulting practice…Read more
Navigating the Minefield – How to make your Outsourcing Initiative a Success
17 April, 2002
Outsourcing has been labeled as one of the most important management ideas of the last five to seven decades. Organisations have been outsourcing activities, however, for many years. Indian companies are just waking up to outsourcing. Carefully navigating the potential minefield that presents itself in every outsourcing relationship, will help your company to make your outsourcing initiative a success.
For more information on PMO Execution consulting…Read more
Emerging Healthcare Landscape of India
23 November, 2017
Emerging Healthcare Landscape of India: The healthcare landscape of India is rapidly evolving and transforming. In this Executive Summary, UC STRATEGY sets out the market dynamics and regulatory changes that are impacting Pharmaceuticals, Medical Technology, Diagnostics, Institutions and Digital Health
For more information on our MedTech consulting practice…Read more
The Future of Indian Biosimilars
29 September, 2009
The evolutionary pressure to merge the boundaries between pharmaceutical and biotechnology companies in order to survive, is increasing. The current view on the Indian biosimilars industry is that at some point in the near future, it will replicate the relative success of the Indian pharma generics industry, in the global markets. The reality may turn out to be quite different. A deep chasm lies ahead for Indian biosimilar manufacturers.